Par Drugs & Che.

Who are the top shareholders of the Par Drugs & Che.?

The top shareholder of Par Drugs & Che. is Jignesh Vallabhbhai Savani, holding 21.88%. Other significant shareholders include Econo Trading And Investment Private Limited at 1.78% and individual investors with a combined stake of 20.3%.

The top shareholders of Par Drugs & Che. include the promoters, with Jignesh Vallabhbhai Savani holding the highest stake at 21.88%. There are no pledged promoter holdings, and the company is also held by two foreign institutional investors, although their combined stake is negligible at 0.0%. The highest public shareholder is Econo Trading And Investment Private Limited, which holds 1.78%. Additionally, individual investors collectively hold 20.3% of the company.

how big is Par Drugs & Che.?

As of Jun 06, Par Drugs & Chemicals Ltd has a market capitalization of 121.98 Cr, classifying it as a Micro Cap company, with net sales of 100.98 Cr and a net profit of 13.36 Cr over the latest four quarters. Shareholder's funds are valued at 85.63 Cr, and total assets amount to 101.61 Cr as of the latest annual period ending in Mar'24.

Market Cap: As of Jun 06, Par Drugs & Chemicals Ltd has a market capitalization of 121.98 Cr, which classifies it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The company reported a sum of Net Sales of 100.98 Cr and a sum of Net Profit of 13.36 Cr for the latest 4 quarters. This data is based on Standalone financials.<BR><BR>Balance Sheet Snapshot: This is also based on Standalone data for the latest annual period ending in Mar'24. The Shareholder's Funds are valued at 85.63 Cr, and the Total Assets amount to 101.61 Cr.

When is the next results date for Par Drugs & Che.?

No Upcoming Board Meetings

What is the bonus history of the Par Drugs & Che.?

Par Drugs & Chemicals Ltd issued a 1:1 bonus on April 27, 2021, with a record date of April 28, 2021, granting shareholders an additional share for each share held.

Par Drugs & Chemicals Ltd has a bonus history that includes a 1:1 bonus issue announced with an ex-date of April 27, 2021. The record date for this bonus was April 28, 2021. This means that shareholders on record as of that date received an additional share for every share they held.

Has Par Drugs & Che. declared dividend?

Par Drugs & Chemicals Ltd has declared a 12% dividend, amounting to 1.2 per share, with an ex-date of November 22, 2021. Despite the dividend declaration, the dividend yield is 0%, and the company has experienced significant volatility in total returns, ranging from -57.37% over 6 months to 495.27% over 5 years.

Par Drugs & Chemicals Ltd has declared a 12% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 12%<BR>- Amount per share: 1.2<BR>- Ex-date: 22 Nov 21<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -57.37%, the dividend return was 0%, resulting in a total return of -57.37%.<BR><BR>In the 1-year period, the price return was -55.99%, the dividend return was 0%, resulting in a total return of -55.99%.<BR><BR>In the 2-year period, the price return was -52.72%, the dividend return was 0%, resulting in a total return of -52.72%.<BR><BR>In the 3-year period, the price return was -32.61%, the dividend return was 0%, resulting in a total return of -32.61%.<BR><BR>In the 4-year period, the price return was 51.47%, the dividend return was 1.31%, resulting in a total return of 52.78%.<BR><BR>In the 5-year period, the price return was 490.29%, the dividend return was 4.98%, resulting in a total return of 495.27%.<BR><BR>Overall, while Par Drugs & Chemicals Ltd has declared a dividend, the dividend yield remains at 0%. The total returns over various periods show significant volatility, with negative returns in the shorter terms and substantial positive returns over the longer term, particularly in the 5-year period.

Who are the peers of the Par Drugs & Che.?

Par Drugs & Che.'s peers include Hindcon Chemical, Mahickra Chem., Arvee Laborat., and others, with varying management and growth risks. All peers have a 1-year return of 0.00%, showing no variation.

Peers: The peers of Par Drugs & Che. are Hindcon Chemical, Mahickra Chem., Arvee Laborat., Unilex Colour &C, Indian Emuls, Ushanti Colour, Shri Ahimsa, Vadivarhe Speci., Hi-Green Carbon, and Sanginita Chemi.<BR><BR>Quality Snapshot: Excellent management risk is observed at Indian Emuls and Shri Ahimsa, while Average management risk is found at Hindcon Chemical, Mahickra Chem., Arvee Laborat., and Hi-Green Carbon, and the rest have Below Average management risk. Growth is Excellent at Indian Emuls, while Average growth is noted at Hi-Green Carbon, and Below Average growth is seen at Hindcon Chemical, Mahickra Chem., Arvee Laborat., Unilex Colour &C, Ushanti Colour, Shri Ahimsa, Vadivarhe Speci., Sanginita Chemi, and the rest. Excellent capital structure is found at Par Drugs & Che. and Shri Ahimsa, Good capital structure is seen at Arvee Laborat. and Hi-Green Carbon, while Average capital structure is noted at Indian Emuls and Below Average at Hindcon Chemical, Mahickra Chem., Unilex Colour &C, Ushanti Colour, Vadivarhe Speci., and Sanginita Chemi.<BR><BR>Return Snapshot: All peers, including Par Drugs & Che., have a 1-year return of 0.00%, indicating no variation among them. There are no peers with a negative six-month return.

What is the technical trend for Par Drugs & Che.?

As of May 12, 2025, Par Drugs & Che exhibits a mildly bearish trend overall, with mixed signals from key indicators such as a mildly bullish weekly MACD and bearish daily moving averages.

As of 12 May 2025, the technical trend for Par Drugs & Che has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD remains bearish. The RSI shows no signal on the weekly chart but is bullish on the monthly. Bollinger Bands are bearish on both weekly and monthly time frames. Daily moving averages are bearish, and the KST is mildly bullish weekly but bearish monthly. Dow Theory shows a mildly bullish trend on the weekly chart with no trend on the monthly. The OBV is mildly bearish weekly and mildly bullish monthly. Overall, the current stance is mildly bearish, with key indicators such as the daily moving averages and Bollinger Bands contributing to this view.

Who are in the management team of Par Drugs & Che.?

As of March 2023, the management team of Par Drugs & Che. includes Falgun Vallabhbhai Savani (Chairman & Managing Director), Jigneshbhai Vallabhbhai Savani (Executive Director & CEO), and several independent and non-executive directors. Key members also include Ghanshayambhai Bhagvanbhai Savani, Nayna Jignesh Savani, Krishna Mitulbhai Shah, Kajal Chintanbhai Vaghani, Pravin Manjibhai Bhayani, and Bintal Bhaveshkumar Shah.

As of March 2023, the management team of Par Drugs & Che. includes the following individuals:<BR><BR>1. Falgun Vallabhbhai Savani - Chairman & Managing Director<BR>2. Jigneshbhai Vallabhbhai Savani - Executive Director & CEO<BR>3. Ghanshayambhai Bhagvanbhai Savani - WTD & Executive Director<BR>4. Nayna Jignesh Savani - Non Executive Director<BR>5. Krishna Mitulbhai Shah - Independent Non Executive Director<BR>6. Kajal Chintanbhai Vaghani - Independent Non Executive Director<BR>7. Pravin Manjibhai Bhayani - Independent Non Executive Director<BR>8. Bintal Bhaveshkumar Shah - Independent Non Executive Director<BR><BR>These individuals play key roles in the governance and management of the company.

What does Par Drugs & Che. do?

Par Drugs and Chemicals Ltd, a Micro Cap company in the Chemicals & Petrochemicals industry, reported net sales of 223 Cr and a net profit of 16 Cr for the quarter ending March 2025. It was incorporated in 1999 and became a Public Limited Company in 2018, with a market cap of INR 116 Cr.

Overview:<BR>Par Drugs and Chemicals Ltd operates in the Chemicals & Petrochemicals industry and is categorized as a Micro Cap company.<BR><BR>History:<BR>The company was originally incorporated in 1999 as a Private Limited Company in Bhavnagar, Gujarat, and was later converted into a Public Limited Company on 5 November 2018. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 223 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 16 Cr (Quarterly Results - Mar 2025)<BR>- Market Cap: INR 116 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 9.00<BR>- Industry P/E: 47<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -0.19<BR>- Return on Equity: 13.81%<BR>- Price to Book: 1.21<BR><BR>Contact Details:<BR>Details: No Company Details Available<BR>Registrar Address: Not available.

How has been the historical performance of Par Drugs & Che.?

Par Drugs & Che. has shown consistent growth in net sales and profits, with net sales increasing from 55.85 Cr in Mar'20 to 100.97 Cr in Mar'25, and profit after tax reaching 13.36 Cr in Mar'25. Despite rising costs and cash flow challenges, the company maintains a healthy profit margin of 13.23%.

Answer:<BR>The historical performance of Par Drugs & Che. shows a consistent growth trend in net sales and profits over the years, with some fluctuations in specific metrics.<BR><BR>Breakdown:<BR>Par Drugs & Che. has demonstrated a steady increase in net sales, rising from 55.85 Cr in Mar'20 to 100.97 Cr in Mar'25. Total operating income has followed a similar trajectory, reaching 100.97 Cr in Mar'25, up from 46.32 Cr in Mar'19. The company's total expenditure, excluding depreciation, increased to 81.47 Cr in Mar'25 from 38.12 Cr in Mar'19, reflecting rising costs, particularly in raw materials, which amounted to 39.41 Cr in Mar'25. Operating profit (PBDIT) has shown variability, peaking at 23.06 Cr in Mar'24 before declining to 21.65 Cr in Mar'25. Profit before tax reached 17.92 Cr in Mar'25, while profit after tax was 13.36 Cr, indicating a healthy profit margin of 13.23%. The company's total assets grew significantly to 119.39 Cr in Mar'25 from 60.12 Cr in Mar'20, with total liabilities also increasing to 119.39 Cr in Mar'25. Cash flow from operating activities was 16.00 Cr in Mar'25, although the net cash outflow was -9.00 Cr, down from a net inflow of 14.00 Cr in Mar'24. Overall, Par Drugs & Che. has shown robust growth in sales and profitability, despite some challenges in cash flow management.

Is Par Drugs & Che. overvalued or undervalued?

As of November 17, 2025, Par Drugs & Chemicals is fairly valued with a PE ratio of 11.95 and an EV to EBIT of 8.99, significantly lower than its expensive peers, but has underperformed the Sensex with a stock return of -65.29%.

As of 17 November 2025, the valuation grade for Par Drugs & Chemicals has moved from very attractive to fair. The company is currently fairly valued based on its financial metrics. Key ratios include a PE ratio of 11.95, an EV to EBIT of 8.99, and an ROCE of 22.22%. <BR><BR>In comparison to its peers, Par Drugs & Chemicals has a PE ratio significantly lower than Solar Industries at 95.31 and Gujarat Fluoroch at 57.85, both of which are deemed very expensive. Additionally, the company’s EV to EBITDA of 6.54 is more favorable than that of Godrej Industries, which stands at 40.96, classified as attractive. Notably, Par Drugs & Chemicals has underperformed the Sensex significantly over the past year, with a stock return of -65.29% compared to the Sensex's 10.54%, reinforcing the notion that the stock may be fairly valued at present.

Are Par Drugs & Chemicals Ltd latest results good or bad?

Par Drugs & Chemicals Ltd's latest results are concerning, with net sales dropping 33.16% to ₹19.61 crores and net profit falling 82.29% to ₹0.85 crores, indicating significant operational challenges and a decline in profitability. Investors should be cautious given these negative trends.

The latest results for Par Drugs & Chemicals Ltd indicate a significant downturn in performance, marking a challenging quarter for the company. In the March 2026 quarter, net sales dropped by 33.16% sequentially to ₹19.61 crores, which is the lowest quarterly sales figure in recent times. Additionally, net profit plummeted by 82.29% to just ₹0.85 crores, reflecting a sharp decline in profitability.<BR><BR>Operating margins also suffered, collapsing to 7.34% from 20.65% in the previous quarter, highlighting severe operational challenges. This deterioration stands in stark contrast to the company's strong nine-month performance, where net profit had surged by 153.36% earlier in the fiscal year.<BR><BR>Overall, the results are concerning, with multiple indicators pointing to operational difficulties and a decline in both revenue and profitability. Investors should be cautious as these trends raise questions about the company's ability to sustain its previous performance levels.

Should I buy, sell or hold Par Drugs & Chemicals Ltd?

Why is Par Drugs & Chemicals Ltd falling/rising?

As of 19-May, Par Drugs & Chemicals Ltd's stock price is rising to 85.50, driven by increased investor interest and outperforming its sector today. However, the long-term outlook is concerning due to significant declines in profits and underperformance against benchmarks.

As of 19-May, Par Drugs & Chemicals Ltd's stock price is rising, currently at 85.50, with a change of 1.52 (1.81%) increase. This rise can be attributed to a few key factors. Firstly, the stock has outperformed its sector by 1.04% today, indicating a relative strength compared to its peers. Additionally, there has been a notable increase in investor participation, with delivery volume on 18 May rising by 144.37% against the 5-day average, suggesting heightened interest from investors.<BR><BR>However, it is important to consider the broader context of the stock's performance. Over the past year, Par Drugs & Chemicals Ltd has generated a return of -20.02%, and it has consistently underperformed against benchmarks like the BSE500 over the last three years. The company has also reported a significant decline in quarterly profits, with PAT falling by -75.6% compared to the previous four-quarter average, and net sales at their lowest level of Rs 19.61 crore.<BR><BR>Despite the current rise in stock price, the long-term outlook remains concerning due to poor growth metrics, with net sales growing at an annual rate of only 8.40% and operating profit at a mere 0.89% over the last five years. The stock is trading at a discount compared to its peers, which may attract some investors, but the overall trend indicates a challenging environment for the company.

Which are the latest news on Par Drugs & Che.?